Fairvalue-Calculator Fairvalue-Calculator
EN DE

Klea Holding (ALKLH) Fair Value & Analysis

Healthcare · FR · Market cap €60.2M

Price€0.1848
Fair Value€0.0800
Upside-56.7%
Quality91/100
Evidence: High Range €0.0600 – €0.0800

Fair value as of: Jun 26, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Klea Holding (ALKLH) currently trades at €0.1848, while our model-based Fair Value estimate is €0.0800 — implying the stock looks roughly 56.7% overvalued today. We read business quality at 91/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

Klea Holding SA, together with its subsidiaries, develops health technologies and services in France, the United Arab Emirates, Saudi Arabia, and the European Union. It operates digitalized medical centers that provide administrative screenings for residency and work visas, preventive health check-ups, and medical fitness tests under the Smart Salem brand. Additionally, the company engages in the production of pharmaceuticals. The company was formerly known as Visiomed Group SA and changed its name to Klea Holding SA in June 2024. Klea Holding SA was founded in 2007 and is headquartered in Paris, France.

Open the full interactive analysis →

Similar stocks

Frequently asked questions

Is Klea Holding (ALKLH) undervalued?
As of Jun 26, 2026, our model estimates a fair value of €0.0800 versus a price of €0.1848 — about −57% (overvalued). Model-based estimate, not financial advice.
What is the fair value of ALKLH?
Our 21-model fair value for Klea Holding is €0.0800 (as of Jun 26, 2026), built from audited fundamentals. The current price is €0.1848.
What is the quality score of ALKLH?
Klea Holding has a Quality Score of 91/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.